CpG-STAT3 inhibitors allowed the targeting of TLR9 expressing PMN-MDSCs, leading to their reprogramming in inflammatory anti-tumor cells in different hematological and solid tumor models [157]. The gene discussed is STAT3; the disease is neoplasm.